Vor Biopharma Inc.
NASDAQ:VORBiotechnology
-$0.34 today
- Market cap
- $966.13M
- Beta
- 1.73
- P/E (TTM)
- -0.0
- EPS (TTM)
- -$2,053.13
Volume 0.79M
Average 1.07M
VOR Depreciation & Amortization
Non-cash asset write-downs added back to net income because no cash left the business.
Vor Biopharma Inc.NASDAQ: VOR
Depreciation & Amortization · Q1 FY2026 · quarter ended Mar 2026
Depreciation & amortization declines year over year
Q1 FY2026 depreciation & amortization of $28K fell 96.6% year over year, behind the -38.1% change in trailing-twelve-month depreciation & amortization. Over 3 fiscal years it compounded at +4.6% a year.
Context
- Depreciation & amortization increased in 2 of the last 3 fiscal years.
What to watch
Whether quarterly growth recovers from -96.6% toward the trailing-twelve-month pace of -38.1%.
Sources:Cash FlowText generated from reported figures; not investment advice.
Depreciation & Amortization history
USD · from the cash flow
- Latest · FY2025
- 2.89M USD
- Year-over-year change
- -18.2%
- 4-year CAGR
- +19.1%
| Period | Period end | Depreciation & Amortization | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 2.89M | -18.2% |
| FY2024 | 2024-12-31 | 3.53M | +1.0% |
| FY2023 | 2023-12-31 | 3.49M | +38.3% |
| FY2022 | 2022-12-31 | 2.53M | +76.1% |
| FY2021 | 2021-12-31 | 1.43M | — |
Depreciation & Amortization vs competitors
How VOR compares with its peers on the latest reported figures
- VOR's LTM Mar 2026 depreciation & amortization of $2.09M is the smallest of the 10 companies compared; the peer median is $11.5M.
- Its year-over-year change of -38.1% is the lowest of 10, against a peer median of -3.1%.
- Over three fiscal years its annual growth of +4.6% compares with a peer median of +9.8%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Sep 2026 | $18.5M | -0.9% | -6.9% | 73.5% | |
| LTM Mar 2026 | $12.88M | -3.1% | +15.8% | — | |
| LTM Mar 2026 | $12.18M | +16.3% | +9.8% | 13.2% | |
| LTM Mar 2026 | $11.71M | -33.0% | -12.3% | 185.5% | |
| LTM Mar 2026 | $11.5M | -33.5% | -6.6% | — | |
| LTM Mar 2026 | $10.18M | +0.4% | +20.7% | — | |
| LTM Mar 2026 | $9.99M | -2.7% | +10.7% | 15.1% | |
| LTM Mar 2026 | $8.74M | -5.0% | +20.5% | — | |
| LTM Mar 2026 | $4.17M | -34.0% | -5.9% | 10.8% | |
| LTM Mar 2026 | $2.09M | -38.1% | +4.6% | — | |
| Peer median (excluding VOR) | $11.5M | -3.1% | +9.8% | 15.1% | |
Competitors are the stored peer set for VOR. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (68.9M) | (92.09M) | (117.86M) | (116.91M) | (695.98M) |
| Depreciation & Amortization | 1.43M | 2.53M | 3.49M | 3.53M | 2.89M |
| Deferred Income Tax | 0 | 0 | 0 | 0 | 0 |
| Stock-Based Compensation | 4.32M | 10.7M | 13.36M | 9.85M | 18.91M |
| Change in Working Capital | (9.19M) | (12.69M) | 650K | 5K | 10.21M |
| Accounts Receivables | 0 | 0 | 0 | 0 | 0 |
| Inventory | 0 | 0 | 0 | 0 | 0 |
| Accounts Payables | 405K | 0 | 2.85M | 2.24M | 0 |
| Other Working Capital | (9.59M) | (12.69M) | (2.2M) | (2.24M) | 10.21M |
| Other Non-Cash Items | 3.19M | 6.42M | 67K | 3.87M | 521.26M |
| Operating Cash Flow | (69.14M) | (85.14M) | (100.29M) | (99.66M) | (142.71M) |
| Capital Expenditures | (3.89M) | (8.46M) | (1.07M) | (229K) | (941K) |
| Acquisitions (Net) | 0 | 0 | 0 | 0 | 0 |
| Purchases of Investments | (87.76M) | (123.19M) | (74.92M) | (9.91M) | (53.66M) |
| Sales of Investments | 0 | 37.56M | 147M | 107M | 5M |
| Other Investing Activities | 0 | 0 | 0 | 0 | 799K |
| Investing Cash Flow | (91.65M) | (94.09M) | 71.01M | 96.86M | (48.8M) |
| Debt Repayment | 0 | 0 | 0 | 0 | 0 |
| Common Stock Issued | 189.2M | 115.98M | 4.58M | 55.83M | 505.13M |
| Common Stock Repurchased | 0 | 0 | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | (1.66M) | 1.17M | (1.64M) | (2.43M) | (1.33M) |
| Financing Cash Flow | 232.91M | 117.14M | 2.94M | 53.39M | 503.81M |
| Effect of Forex Changes | 0 | 0 | 0 | 0 | 0 |
| Net Change in Cash | 72.12M | (62.1M) | (26.35M) | 50.59M | 312.29M |
| Free Cash Flow | (73.04M) | (93.61M) | (101.36M) | (99.89M) | (143.65M) |
Vor Biopharma Inc.
NASDAQ:VOR
Intrinsic Alpha fair value
Locked
Current Price
$17.83
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.